PA8567701A1 - B3-ADRENERGIC RECEIVER AGONISTS - Google Patents

B3-ADRENERGIC RECEIVER AGONISTS

Info

Publication number
PA8567701A1
PA8567701A1 PA20038567701A PA8567701A PA8567701A1 PA 8567701 A1 PA8567701 A1 PA 8567701A1 PA 20038567701 A PA20038567701 A PA 20038567701A PA 8567701 A PA8567701 A PA 8567701A PA 8567701 A1 PA8567701 A1 PA 8567701A1
Authority
PA
Panama
Prior art keywords
adrenergic
agonists
beta3
receiver agonists
receiver
Prior art date
Application number
PA20038567701A
Other languages
Spanish (es)
Inventor
Bradley Paul Morgan
Jennifer Anne Lafontaine
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PA8567701A1 publication Critical patent/PA8567701A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

LA PRESENTE INVENCION PROPORCIONA AGONISTAS DEL RECEPTOR BETA3-ADRENERGICO DE FORMULA ESTRUCTURAL (I), ASI COMO FORMULACIONES FARMACEUTICAS DE LOS MISMOS, Y METODOS PARA TRATAR ENFERMEDADES, TRASTORNOS Y/O AFECCIONES MEDIADOS POR EL RECEPTOR BETA3-ADRENERGICO UTILIZANDO DICHOS COMPUESTOS.THIS INVENTION PROVIDES BETA3-ADRENERGIC RECEIVER AGONISTS OF STRUCTURAL FORMULA (I), AS WELL AS PHARMACEUTICAL FORMULATIONS OF THE SAME, AND METHODS TO TREAT DISEASES, DISORDERS AND / OR AFFECTIONS MEDIATED BY THE BETA3-ADRENOS RECEIVER.

PA20038567701A 2002-02-27 2003-02-26 B3-ADRENERGIC RECEIVER AGONISTS PA8567701A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36025102P 2002-02-27 2002-02-27

Publications (1)

Publication Number Publication Date
PA8567701A1 true PA8567701A1 (en) 2003-11-12

Family

ID=27766207

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20038567701A PA8567701A1 (en) 2002-02-27 2003-02-26 B3-ADRENERGIC RECEIVER AGONISTS

Country Status (13)

Country Link
EP (1) EP1485379A1 (en)
JP (1) JP2005518448A (en)
AU (1) AU2003248356A1 (en)
BR (1) BR0308070A (en)
CA (1) CA2476316A1 (en)
DO (1) DOP2003000587A (en)
GT (1) GT200300043A (en)
MX (1) MXPA04007127A (en)
PA (1) PA8567701A1 (en)
PE (1) PE20030943A1 (en)
TW (1) TW200408637A (en)
UY (1) UY27680A1 (en)
WO (1) WO2003072572A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002085297A2 (en) 2001-04-24 2002-10-31 East Carolina University Compositions & formulations with a non-glucocorticoid steroid &/or a ubiquinone & kit for treatment of respiratory & lung disease
US7405207B2 (en) 2002-06-17 2008-07-29 Epigenesis Pharmaceuticals, Inc. Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
GB0324654D0 (en) * 2003-10-22 2003-11-26 Glaxo Group Ltd Medicinal compounds
JP4618250B2 (en) * 2003-12-23 2011-01-26 アステラス製薬株式会社 Amino alcohol derivative
DE102004021779A1 (en) * 2004-04-30 2005-11-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg New beta-agonists, process for their preparation and their use as medicines
JP5173190B2 (en) 2004-08-25 2013-03-27 武田薬品工業株式会社 Preventive and therapeutic agent for stress urinary incontinence and screening method thereof
PE20091825A1 (en) 2008-04-04 2009-12-04 Merck & Co Inc HYDROXIMETHYL PYRROLIDINES AS AGONISTS OF THE BETA 3 ADRENERGIC RECEPTOR
EP2771006B1 (en) 2011-10-27 2016-05-25 Merck Sharp & Dohme Corp. Process for making beta 3 angonists and intermediates
EP2770996B1 (en) 2011-10-27 2016-09-28 Merck Sharp & Dohme Corp. Process for making beta 3 agonists and intermediates
HUE045260T2 (en) 2013-03-15 2019-12-30 Merck Sharp & Dohme Process for preparing beta 3 agonists and intermediates

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO179246C (en) * 1991-11-20 1996-09-04 Sankyo Co Aromatic amino-alcohol derivatives and intermediates for their preparation
KR100327273B1 (en) * 1994-04-08 2002-05-10 고사이 아끼오 Ether compound, use thereof, and intermediate for producing the compound
JPH11504649A (en) * 1995-05-10 1999-04-27 ファイザー・インコーポレーテッド β-adrenergic agonist
GB9812709D0 (en) * 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds
WO2002032897A1 (en) * 2000-10-20 2002-04-25 Pfizer Products Inc. Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists

Also Published As

Publication number Publication date
GT200300043A (en) 2003-09-22
WO2003072572A1 (en) 2003-09-04
UY27680A1 (en) 2003-10-31
AU2003248356A1 (en) 2003-09-09
MXPA04007127A (en) 2005-07-05
PE20030943A1 (en) 2003-11-08
DOP2003000587A (en) 2003-08-30
CA2476316A1 (en) 2003-09-04
BR0308070A (en) 2004-12-21
TW200408637A (en) 2004-06-01
EP1485379A1 (en) 2004-12-15
JP2005518448A (en) 2005-06-23
WO2003072572A8 (en) 2004-01-29

Similar Documents

Publication Publication Date Title
CL2011001263A1 (en) Compounds derived from optionally substituted pyrimidinones; pharmaceutical composition that includes them; and its use as phosphodiesterase 1 (pde1) inhibitors for the treatment of diseases involving disorders of the intracellular trajectory of the dopamine d1 receptor such as parkinson's, Alzheimer's, depression, bipolar disease, hypertension, glaucoma.
UY28766A1 (en) ADDITIONAL HETEROPOLYCLIC COMPOUNDS AND THEIR USE AS ANTAGONISTS OF THE METABOTROPIC GLUTAMATE RECEIVER
ECSP077421A (en) COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF THE ACTIVITY OF THE CANABINOID RECEIVER 1
NO20073182L (en) Indazol-carboxamide
CY1111977T1 (en) PEPERIDIN-4-YL-PYRIDAZIN-3-YLAMINE DERIVATIVES AS HIGHLY DISTRIBUTED DOPAMIN COMPONENTS 2
ATE441646T1 (en) 5-HT4 RECEPTOR AGONIST COMPOUNDS
GT200800198A (en) COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF THE ACTIVITY OF THE CANABINOID RECEIVER OF TYPE 1.
ATE431824T1 (en) QUINOLINONE-CARBOXAMIDE COMPOUNDS
PA8675701A1 (en) NEW DERIVATIVES OF FLUORENE, COMPOSITIONS THAT CONTAIN THEM AND ITS USE
ECSP034428A (en) CYCLOPENTHANOLS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND THEIR USE
ECSP10010518A (en) HYDROXIMETHYL PIRROLIDINS AS AGONISTS OF THE BETA 3 ADRENERGIC RECEIVER
PA8663501A1 (en) DERIVATIVES OF INDOL, BENZOTIOFEN, BENZOFURAN AND INDENO CICLOALQUILCONDENSADOS
PA8840801A1 (en) DIOXA-BICYCLE DERIVAOS [3.2.1] OCTANO-2,3,4-TRIOL
CR9749A (en) XANTINA DERIVATIVES AS SELECTIVE HM74A AGONISTS
CY1111169T1 (en) BENZOIMIDAZOL-2-YL PYRIMIDINES AND PYRAZINS AS MODIFICATES OF THE H4 HISTORY RECEPTOR
CR10497A (en) USEFUL PIPERAZINYL DERIVATIVES IN THE TREATMENT OF DISEASES MEDIATED BY THE GPR38 RECEIVER
AR054786A1 (en) (6-FLUOR-BENZOL (1,3) DIOXOLIL) -MORFOLIN-4-IL-METANOMAS, CB1 RECEIVER MODULATORS
ECSP088511A (en) NEUROPEPTIDO-2 RECEIVER AGONISTS
ECSP034811A (en) DERETADOS HETEROCICLILOXI-, -TIOXI - Y - AMINOBENZAZOLE SUCH AS LIGANDOS 5-HIDROXITRIPTAMINA-6
UY29414A1 (en) PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS
UY30572A1 (en) N- (1-FTALAZIN-1-IL-PIPERIDIN-4-IL) -AMIDAS AS MODULATORS OF THE EP2 RECEIVER
CY1113759T1 (en) HIGHLY DISTRIBUTED DOPAMINE COMPETITORS 2
BRPI0820668A2 (en) 5-HALOGEN SUBSTITUTED OXINDOL DERIVATIVES AND THEIR USE TO TREAT VASOPRESSIN DEPENDENT DISEASES
CR11562A (en) BIS-PIRIDILPIRIDONAS AS ANTAGONISTS OF THE RECEIVER 1 OF THE CONCENTRATING HORMONE OF MELANINA
ECSP045473A (en) DERIVATIVES OF 1- (AMINOALQUIL) -3-SULFONYLINDOL AND 1-AMINOALQUIL-3-SULFONYLINDAZOL AS 5-HYDROXYTHYRIPTAMINE-6 LIGANDS